Patients should confirm the exact medication, pharmacy, formulation, dosing instructions, and regulatory status before starting any treatment
At Elite Health Center NYC, we want every patient to use their compounded semaglutide effectively and safely
In SURMOUNT-2, the mean WL was up to 15.7% with tirzepatide 15 mg compared to 3.3% WL with placebo at 72 weeks for people with obesity and T2D [47]
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that activates: GLP-1 (glucagon-like peptide-1) receptor GIP (glucose-dependent insulinotropic polypeptide) receptor Glucagon (GCG) receptor This triple G mechanism targets multiple pathways for appetite control, insulin sensitivity, glucose regulation, and energy/fat metabolismpotentially offering greater effects than dual (GLP-1/GIP) or single agonists
Boost metabolism and energy levels
The 12mg dose, which produces 24-29% weight loss, carries theoretically higher risk than the 1mg dose at 8.7% weight loss
